The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: Experience from the patient perspective

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 6, 2014, Pages 929-940

  Gupta, Shaloo ^a   Zhang, Jie ^b   Jerusalem, Guy ^c  

^a KANTAR HEALTH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Chemotherapy; Health related quality of life; Hormonal therapy; Metastatic breast cancer; Oncology; Patient reported outcomes

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HORMONE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG RESPONSE; DRUG SAFETY; FAMILY LIFE; FATIGUE; FEMALE; HAIR LOSS; HOT FLUSH; HUMAN; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NAUSEA; PATIENT SATISFACTION; PRODUCTIVITY; QUALITY OF LIFE; SLEEP DISORDER; TREATMENT OUTCOME; VOMITING; XEROSTOMIA; BREAST NEOPLASMS; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; COST OF ILLNESS; DECISION SUPPORT SYSTEM; DEFICIENCY; DRUG EFFECTS; EUROPE; HEALTH CARE SURVEY; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT SELECTION; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS; STATISTICAL MODEL; TIME; UNITED STATES;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DECISION SUPPORT TECHNIQUES; EUROPE; FEMALE; HEALTH CARE SURVEYS; HUMANS; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PATIENT SATISFACTION; PATIENT SELECTION; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84909947446     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.949243     Document Type: Article

References (37)

1. WHO. Available from: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx [Last accessed 16 January 2014]
2. American Cancer Society. Global cancer facts & figures. 2nd edition. American Cancer Society, Atlanta; 2011. Available from: www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf [Last accessed 25 November 2013]
3. Surveillance, epidemiology, and end results (SEER) program. SEER cancer statistics factsheets: breast cancer. National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/statfacts/html/breast.html [Last accessed 25 November 2013]
4. Cardoso F, Harbeck N, Fallowfield L, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-19
5. Johnson RH, Chien FI, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 2013;309(8):800-5
6. Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early-stage breast cancer. Breast Cancer Res Treat 2013;137(2):449-55
7. Cardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009;101(17):1174-81
8. Partridge AH, Burstein HJ, Winder EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 2001(30):135-42
9. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21(3):242-52
10. Lorizio W, Wu AH, Beattie MS, et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 2012;132(3):1107-18
11. Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012;13(4):e148-60
12. Chim K, Xie SX, Stricker CT, et al. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 2013;3:13-401
13. Campbell JD, Ramsey SD. The costs of treating cancer in the US: a synthesis of published evidence. Pharmacoeconomics 2009;27(3):199-209
14. Foster TS, Miller JD, Boye ME, et al. The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev 2011;37(6):405-15
15. Montero AJ, Eapen S, Gorin B, Adler P. The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat 2012;134(2):815-22
16. Sorenson SV, Goh JW, Pan F, et al. Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int J Technol Assess Health Care 2012;28(1):12-21
17. Fu AZ, Chen L, Sullivan SD, Christiansen NP. Absenteeism and short-term disability associated with breast cancer. Breast Cancer Res Treat 2011;130(1):235-42
18. Høyer M, Johansson B, Nordin K, et al. Health-related quality of life among women with breast cancer - a population-based study. Acta Oncol (Madr) 2011;50(7):1015-26
19. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008;27:32
20. Dragomir BI, Fodoreanu L. Correlations between state anxiety and quality of life in metastatic breast cancer patients. Rev Med Chir Soc Med Nat Iasi 2013;117(3):610-15
21. Carlson RW. Quality of life issues in the treatment of metastatic breast cancer. Oncology 1998;12(3 Suppl 4):27-31
22. Costantino J. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. Clin Therap 2002;24(Suppl C):C26-42
23. Kurtz JE, Dufour P. Strategies for improving quality of life in older patients with metastatic breast cancer. Drugs Aging 2002;19(8):605-22
24. Svensson H, Hatschek T, Johansson H, et al. Health-related quality of life as prognostic factor in response, progression-free survival, and survival in women with metastatic breast cancer. Med Oncol 2012;29(2):432-8
25. Lee CK, Stockler MR, Coates AS, et al. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer 2010;102(9):1341-7
26. Harrison PL, Pope JE, Coberley CR, Rula EY. Evaluation of the relationship between individual well-being and future health care utilization and cost. Popul Health Manag 2012;15(6):325-30
27. Basch E. Toward patient-centered drug development in oncology. N Engl J Med 2013;369(5):397-400
28. Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003(2):CD002747
29. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47(11):1245-51
30. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4(5):353-65
31. Abetz L, Coombs JH, Keininger DL, et al. Development of cancer therapy satisfaction questionnaire: item generation and content validity testing. Value Health 2005;8(Suppl 1):S41-53
32. Trask PC, Tellefsen C, Espindle D, et al. Psychometric validation of the cancer therapy satisfaction questionnaire. Value Health 2008;11(4):669-79
33. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997;15(3):974-86
34. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 1993;11(3):570-9
35. Eton DT, Cella D, Yost KJ, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004;57(9):898-910
36. Carlson RW, Allred DC, Anderson BO, et al. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10(7):821-9
37. Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010;102(7):56-63